OrthoPediatrics (NASDAQ:KIDS) Director David Pelizzon Sells 18,000 Shares of Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) Director David Pelizzon sold 18,000 shares of the stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $24.28, for a total value of $437,040.00. Following the sale, the director owned 6,863,464 shares of the company’s stock, valued at approximately $166,644,905.92. This represents a 0.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

OrthoPediatrics Stock Down 1.9%

NASDAQ:KIDS opened at $24.03 on Thursday. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28. OrthoPediatrics Corp. has a twelve month low of $14.42 and a twelve month high of $26.74. The company has a market cap of $627.42 million, a PE ratio of -14.30 and a beta of 0.98. The company’s 50 day moving average is $21.23 and its two-hundred day moving average is $18.58.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The firm had revenue of $70.51 million for the quarter, compared to analyst estimates of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. Analysts anticipate that OrthoPediatrics Corp. will post -1.14 EPS for the current year.

Hedge Funds Weigh In On OrthoPediatrics

A number of hedge funds and other institutional investors have recently bought and sold shares of KIDS. Russell Investments Group Ltd. increased its stake in OrthoPediatrics by 433.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after buying an additional 1,139 shares during the period. Legal & General Group Plc acquired a new stake in shares of OrthoPediatrics in the 2nd quarter worth $34,000. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of OrthoPediatrics by 5,226.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after acquiring an additional 2,561 shares in the last quarter. Caption Management LLC purchased a new stake in shares of OrthoPediatrics in the third quarter valued at about $54,000. Finally, BNP Paribas Financial Markets increased its stake in shares of OrthoPediatrics by 60.2% during the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after acquiring an additional 1,235 shares during the period. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting OrthoPediatrics

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: OrthoPediatrics completed the full U.S. commercial launch of its 3P™ Pediatric Plating Platform® Hip System after more than 350 successful implantations during a limited release. The company said the system addresses pediatric hip trauma and deformities, improves fixation and surgical workflow, and is the first of several planned systems in a broader plating portfolio. The launch provides a potential long-term revenue and market-share opportunity, although the company did not provide specific financial guidance. OrthoPediatrics Announces Full Commercial Launch of 3P Pediatric Plating Platform Hip System
• Neutral Sentiment: Reported short interest was listed as zero shares with a zero-day short-interest ratio. However, the filing data also showed an invalid “NaN” change, making the statistic unreliable and providing little usable insight into potential short-selling pressure.
• Negative Sentiment: Director David R. Pelizzon and major shareholder entities associated with Squadron Capital and Jennifer N. Pritzker reported sales totaling 38,300 shares for approximately $943,302 across August 24–26, at prices ranging from $24.28 to $25.75. The transactions reduced the reported position by only about 0.56%, leaving ownership of roughly 6.86 million shares, so the sales appear relatively small compared with the remaining stake. Nevertheless, repeated insider selling can weigh on sentiment, particularly with KIDS trading near its 52-week high. SEC insider transaction filing

Wall Street Analysts Forecast Growth

KIDS has been the subject of several analyst reports. Weiss Ratings upgraded OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. BTIG Research lifted their price objective on shares of OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Needham & Company LLC upped their price target on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Piper Sandler restated an “overweight” rating and issued a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $26.44.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.